More potent second- and third- generation ALK inhibitors, such as ceritinib, lorlatinib, brigatinib, alectinib, and repotrectinib, have shown improved therapeutic activity in neuroblastomas with ALK mutations, though they achieve complete responses in only a small number of patients (130–135). The gene discussed is ALK; the disease is neuroblastoma.